Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7588463rdf:typepubmed:Citationlld:pubmed
pubmed-article:7588463lifeskim:mentionsumls-concept:C0085637lld:lifeskim
pubmed-article:7588463lifeskim:mentionsumls-concept:C0006949lld:lifeskim
pubmed-article:7588463lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:7588463pubmed:issue11lld:pubmed
pubmed-article:7588463pubmed:dateCreated1995-11-30lld:pubmed
pubmed-article:7588463pubmed:abstractTextA 32-year-old man with mental retardation and uncontrolled complex partial epilepsy receiving carbamazepine (CBZ) and divalproex sodium (VPA), developed frequent episodes of forced upward gaze after increase in the daily VPA dosage. CBZ dosage was decreased, with prompt resolution of symptoms. The upward gaze problem recurred several months later. CBZ dosage was decreased further with subsequent resolution of symptoms. Therefore, the oculogyric crisis (OGC) appeared to be induced by CBZ.lld:pubmed
pubmed-article:7588463pubmed:languageenglld:pubmed
pubmed-article:7588463pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7588463pubmed:citationSubsetIMlld:pubmed
pubmed-article:7588463pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7588463pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7588463pubmed:statusMEDLINElld:pubmed
pubmed-article:7588463pubmed:monthNovlld:pubmed
pubmed-article:7588463pubmed:issn0013-9580lld:pubmed
pubmed-article:7588463pubmed:authorpubmed-author:GormazAAlld:pubmed
pubmed-article:7588463pubmed:authorpubmed-author:BarkleyG LGLlld:pubmed
pubmed-article:7588463pubmed:issnTypePrintlld:pubmed
pubmed-article:7588463pubmed:volume36lld:pubmed
pubmed-article:7588463pubmed:ownerNLMlld:pubmed
pubmed-article:7588463pubmed:authorsCompleteYlld:pubmed
pubmed-article:7588463pubmed:pagination1158-60lld:pubmed
pubmed-article:7588463pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7588463pubmed:meshHeadingpubmed-meshheading:7588463-...lld:pubmed
pubmed-article:7588463pubmed:meshHeadingpubmed-meshheading:7588463-...lld:pubmed
pubmed-article:7588463pubmed:meshHeadingpubmed-meshheading:7588463-...lld:pubmed
pubmed-article:7588463pubmed:meshHeadingpubmed-meshheading:7588463-...lld:pubmed
pubmed-article:7588463pubmed:meshHeadingpubmed-meshheading:7588463-...lld:pubmed
pubmed-article:7588463pubmed:meshHeadingpubmed-meshheading:7588463-...lld:pubmed
pubmed-article:7588463pubmed:meshHeadingpubmed-meshheading:7588463-...lld:pubmed
pubmed-article:7588463pubmed:meshHeadingpubmed-meshheading:7588463-...lld:pubmed
pubmed-article:7588463pubmed:meshHeadingpubmed-meshheading:7588463-...lld:pubmed
pubmed-article:7588463pubmed:year1995lld:pubmed
pubmed-article:7588463pubmed:articleTitleOculogyric crisis induced by carbamazepine.lld:pubmed
pubmed-article:7588463pubmed:affiliationDepartment of Neurology, Henry Ford Hospital, Detroit, Michigan 48202, USA.lld:pubmed
pubmed-article:7588463pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7588463pubmed:publicationTypeCase Reportslld:pubmed